Next Article in Journal
Plasma-Based Degradation of Mycotoxins Produced by Fusarium, Aspergillus and Alternaria Species
Next Article in Special Issue
HDAC8 Prevents Anthrax Lethal Toxin-induced Cell Cycle Arrest through Silencing PTEN in Human Monocytic THP-1 Cells
Previous Article in Journal
Individual and Combined Cytotoxic Effects of   Co‐Occurring Deoxynivalenol Family Mycotoxins on  Human Gastric Epithelial Cells
Previous Article in Special Issue
A Simple Luminescent Adenylate-Cyclase Functional Assay for Evaluation of Bacillus anthracis Edema Factor Activity
Open AccessArticle

A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection

Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA
School of Mechanical Engineering, National Technical University of Athens, Zografou 15780, Greece
Author to whom correspondence should be addressed.
Academic Editor: Shihui Liu
Toxins 2017, 9(3), 99;
Received: 5 January 2017 / Revised: 27 February 2017 / Accepted: 7 March 2017 / Published: 10 March 2017
(This article belongs to the Collection Anthrax Toxins)
Developing drugs to treat the toxic effects of lethal toxin (LT) and edema toxin (ET) produced by B. anthracis is of global interest. We utilized a computational approach to score 474 drugs/compounds for their ability to reverse the toxic effects of anthrax toxins. For each toxin or drug/compound, we constructed an activity network by using its differentially expressed genes, molecular targets, and protein interactions. Gene expression profiles of drugs were obtained from the Connectivity Map and those of anthrax toxins in human alveolar macrophages were obtained from the Gene Expression Omnibus. Drug rankings were based on the ability of a drug/compound’s mode of action in the form of a signaling network to reverse the effects of anthrax toxins; literature reports were used to verify the top 10 and bottom 10 drugs/compounds identified. Simvastatin and bepridil with reported in vitro potency for protecting cells from LT and ET toxicities were computationally ranked fourth and eighth. The other top 10 drugs were fenofibrate, dihydroergotamine, cotinine, amantadine, mephenytoin, sotalol, ifosfamide, and mefloquine; literature mining revealed their potential protective effects from LT and ET toxicities. These drugs are worthy of investigation for their therapeutic benefits and might be used in combination with antibiotics for treating B. anthracis infection. View Full-Text
Keywords: drug repurposing; anthrax; computation; signaling network of a drug drug repurposing; anthrax; computation; signaling network of a drug
Show Figures

Graphical abstract

MDPI and ACS Style

Bai, J.P.F.; Sakellaropoulos, T.; Alexopoulos, L.G. A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection. Toxins 2017, 9, 99.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop